Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Study of LusPACercept in Participants With Myelofibrosis Associated Anemia and Thrombocytopenia

9. November 2026 aktualisiert von: Case Comprehensive Cancer Center

A Phase 2 Multi-Institutional Study of Combination of Luspatercept With Pacritinib (LusPACercept) in Patients With Myelofibrosis Associated Anemia and Thrombocytopenia

This study is for participants who have been diagnosed with myelofibrosis with cytopenia. Luspatercept and Pacritinib are experimental drug combination that works by blocking certain enzymes to calm an overactive inmmune system to reduce inflammation which would allow red blood cells to mature. The purpose of this study is to find out if the combination of Luspatercept and Pacritinib can help improve hemobglobin or transfusion dependents in participants with myelofibrosis with cytopenias.

Studienübersicht

Status

Noch keine Rekrutierung

Bedingungen

Detaillierte Beschreibung

Myelofibrosis is a type of bone cancer that mainly affects the elderly. Myeolofibrosis can either develop on its own, or it can be caused by other blood cell conditions. Myeolofibrosis causes scarring in the bone marrow that makes it hard to produce healthy read blood cells. This increases the risk of participants developing anemia at diagnosis, but eventually most affected participants develop anemia. Anemia is a complication of using Janus Kinase inhibitors, which are the main agents used to treat MF. Almost half of the participants who develop anemia require red blood cell transfusion support. Anemia causes poor quality of life, especially in participants who are transfusion dependent.

The goal of this study is to find out if using a combination of Luspatercept and Pacritinib can help decrease anemia in particpants with MF and improve the quality of life by requiring less blood transfusions. This combination works by blocking certain enzymes to calm an overactive immune system and reduce inflammation. This allows red blood cells to mature. Luspatercept will be given through subcutaneous injections on the first day of the study cycle, and pacritinib will be given in an oral pill that will be taken 2 times per day. About 50 participants are planned to be enrolled in the study.

Studientyp

Interventionell

Einschreibung (Geschätzt)

50

Phase

  • Phase 2

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

  • Name: Akriti Jain, MD, FACP
  • Telefonnummer: 216 445-7942
  • E-Mail: JAINA9@ccf.org

Studienorte

    • Ohio
      • Cleveland, Ohio, Vereinigte Staaten, 44196
        • Cleveland Clinic Foundation
        • Kontakt:
          • Akriti G Jain, MD, FACP
          • Telefonnummer: 216 445-7942
          • E-Mail: JAINA9@ccf.org
        • Hauptermittler:
          • Akriti G Jain, MD, FACP

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Patients with myelofibrosis as defined by WHO criteria - either primary or secondary myelofibrosis with:

    • Anemia:

      • Transfusion Dependent: ≥3 units transfused in the 12 weeks immediately preceding C1D1.
      • Non-Transfusion Dependent: had ≥3 Hb level measurements of ≤10 g/dL recorded on ≥3 different days with no RBC transfusions in the 12 weeks immediately preceding C1D1.
    • Thrombocytopenia: Platelet count of ≤150 at any time after signing informed consent.

  • Age ≥18 years

  • Participant has an Eastern Cooperative Oncology Group (ECOG) performance score of ≤ 2.

  • A female of childbearing potential (FCBP) for this study is defined as a female who: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (eg, has had menses at any time in the preceding 24 consecutive months). Females of childbearing potential (FCBP) participating in the study must:

    • Have 2 negative pregnancy tests as verified by the Investigator prior to starting study therapy. She must agree to ongoing pregnancy testing during the study, and after end of IP. This applies even if the participant practices true abstinence* from heterosexual contact.

    • Either commit to true abstinence* from heterosexual contact (which must be reviewed on a monthly basis and source documented) or agree to use, and be able to comply with, effective contraception# 28 days prior to starting IP, during the study therapy (including dose interruptions), and for 12 weeks (approximately 5 times the mean terminal half-life of IP based on multiple-dose PK data) after discontinuation of study therapy.

      • Subjects must avoid concomitant use of pacritinib with hormonal contraceptives except for intrauterine systems containing levonorgestrel. The effectiveness of hormonal contraceptives, except for intrauterine systems containing levonorgestrel, may be reduced when used with pacritinib. If contraception is needed or desired, an alternate contraceptive that is not affected by CYP3A4 inducers (e.g., an intrauterine system) or additional nonhormonal contraceptive (e.g., condoms) should be used when treated concomitantly with pacritinib, and for 30 days after last dose of pacritinib
  • Male participants must:

Practice true abstinence* (which must be reviewed on a monthly basis) or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential who is or is not using contraception** while participating in the study, during dose interruptions and for at least 12 weeks (approximately 5 times the mean terminal half-life of IP based on multiple-dose PK data) following IP discontinuation, even if he has undergone a successful vasectomy.

  • True abstinence is acceptable when it is in line with the preferred and usual lifestyle of the participant. [Periodic abstinence (eg, calendar, ovulation, symptothermal, postovulation methods) and withdrawal are not acceptable methods of contraception.]

    • Agreement to use highly effective methods of contraception that alone or in combination result in a failure rate of a Pearl index of less than 1% per year when used consistently and correctly throughout the course of the study. Such methods include: Placement of an intrauterine device (IUD); Bilateral tubal occlusion; Vasectomized partner; Sexual Abstinence.

      • Participant is willing and able to adhere to the study visit schedule and other protocol requirements including the use of the electronic patient reported outcomes device.
      • Participants must have the ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

  • Prior use of Luspatercept, Sotatercept, Elritercept or any other activin ligand traps, pacritinib or Momelotinib for any duration. Prior Ruxolitinib or Fedratinib are permissible with a wash out period of 2 weeks prior to C1D1.
  • Participant participation in any other clinical protocol or investigational trial that involves use of experimental therapy (including investigational agents) and/or therapeutic devices within 30 days or for investigational agents within five half-lives, whichever comes later, by the end of the screening period.
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to luspatercept or pacritinib.
  • Participants with uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, gastrointestinal (GI) disease, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

4.2.5. Participant with anemia from cause other than MF or JAK2 inhibitor therapy (eg, iron deficiency, vitamin B12 and/or folate deficiencies, autoimmune or hemolytic anemia, infection, or any type of known clinically significant bleeding or sequestration).

  • Participant use of hydroxyurea, immunomodulatory compounds such as pomalidomide, thalidomide, ESAs, androgenic steroids, strong CYP3A4 inhibitors and inducers, or other drugs with potential effects on hematopoiesis ≤ 2 weeks up to the end of the screening period.

    • Systemic corticosteroids are permitted for nonhematological conditions providing the participant is receiving a constant dose equivalent to ≤ 10 mg prednisone for the 4 weeks immediately up to the end of the screening period. Use of topical steroids (drops, inhaler, ointment etc.) are permitted.
    • Iron chelation therapy (ICT) is permitted providing the participant is receiving a stable dose for the 8 weeks up to the end of the screening period.
  • Participant with any of the following laboratory abnormalities at screening:

    • Neutrophils: < 0.5 x 109/L
    • White blood count (WBC): > 100 x 109/L
    • Peripheral blood myeloblasts: > 10%
    • PT or INR and PTT or aPTT >=1.5x ULN (this exclusion criteria would not apply for patients on anticoagulation).
    • Estimated glomerular filtration rate: < 30 mL/min/1.73 m2 (via the 4-variable modification of diet in renal disease [MDRD] formula) or nephrotic participants (eg, urine albumin-to-creatinine ratio > 3500 mg/g)
    • Aspartate aminotransferase (AST) or alanine aminotransferase (ALT): > 3.0 x upper limit of normal (ULN)
    • Direct bilirubin: ≥ 2 x ULN
    • Severe hepatic impairment defined as Child-Pugh Class C (score ≥10)
    • Higher levels are acceptable if these can be attributed to active red blood cell precursor destruction within the bone marrow (eg, ineffective erythropoiesis) or due to pre-existing Gilbert's disease.
  • Participant with prior history of malignancies, other than disease under study, unless the participant has been free of the disease for ≥ 3 years. However, participants with the following history/concurrent conditions are allowed (if they have already undergone treatment with curative intent):

    • Basal or squamous cell carcinoma of the skin
    • Carcinoma in situ of the cervix
    • Carcinoma in situ of the breast
    • Incidental histologic finding of prostate cancer (T1a or T1b using the tumor, nodes, metastasis [TNM] clinical staging system)
  • Participant with a major bleeding event (defined as symptomatic bleeding in a critical area or organ and/or bleeding causing a decrease in Hgb of ≥ 2 g/dL or leading to transfusion of ≥ 2 units of packed red cells) in the last 3 months prior to the end of the screening period.

  • Participant with uncontrolled systemic fungal, bacterial, or viral infection (defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics, antiviral therapy, and/or other treatment).

  • Pregnant or breastfeeding females.

  • Subjects with QTc >480 (unless QRS prolongation >120 msec, in which case QTC up to 500 is acceptable)

  • Subjects who have experienced a thrombotic or embolic event during 6 months prior to first planned dose of luspatercept.

  • Subjects who have experienced a major cardiac event within 6 months prior to enrollment, including but not limited to hospitalization for congestive heart failure (CHF), myocardial infarction (MI), or clinically significant arrhythmia requiring medical intervention

  • Subjects who have experienced symptomatic heart failure defined as New York Heart Association (NYHA) Class II or greater at the time of enrollment

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Nicht randomisiert
  • Interventionsmodell: Einzelgruppenzuweisung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: LusPACercept combination

Luspatercept will be given through subcutaneous injection on Day 1of each cycle at a starting dose of 1.33 milligrams/kilogram and can go up to a maximum dose of 1.75 milligrams/kilogram. Pacritinib will be given twice daily orally at a dose of 200 milligrams. Each cycle lasts 21 days.

Luspatercept will be given through subjecutaneous injection on Day 1of each cycle at a dose of 1.33-1.75mg/kg.

Pacritinib will be given twice daily orally at a dose of 200mg.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Rate of major response for anemia
Zeitfenster: week 24

The rate of major response for anemia is defined as per 2024 IWG-ELN response criteria for transfusion dependent and non-transfusion dependent partipants with myelofibrosis.

week 24

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Rate of minor response for anemia
Zeitfenster: week 24

Minor response for anemia is defined as per 2024 IWG-ELN response criteria for transfusion dependent and non-transfusion dependent partipants with myelofibrosis.

week 24
Safety of luspatrecept and pacritinib combination
Zeitfenster: up to 24 weeks

Incidence and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) according to the CTCAE.

up to 24 weeks
Tolerability of luspatrecept and pacritinib combination
Zeitfenster: up to 24 weeks

Incidence and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) according to the CTCAE.

up to 24 weeks
Proportion of participants achieving an anemia response
Zeitfenster: up to 24 weeks

Anemia response during the entire treatment period, defined as a greater than or equal to 1.5 g/dL increase in hemoglobin during the entire treatment period

up to 24 weeks
Time to anemia response
Zeitfenster: up to 24 weeks

Defined as time from first dose to first onset of anemia response during the 24 week primary treatment period

up to 24 weeks
Duration of anemia response
Zeitfenster: up to 24 weeks

Defined as the amount of time from the onset of longest anemia response to loss of that response per IWG ELN 2024 criteria during the primary treatment period

up to 24 weeks
Proportion of participants achieving a greater than 50% reduction in total symptom score
Zeitfenster: up to 24 weeks

As defined by the myeolofibrosis Symptom Assessment form v.4.0 (MF-SAF)

up to 24 weeks
Change in spleen size
Zeitfenster: up to 24 weeks

Evaluate change in spleen size, assessed by spleen length on ultrasound and palpable spleen length below the left costal margin

up to 24 weeks

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Ermittler

  • Hauptermittler: Akriti Jain, MD, FACP, The Cleveland Clinic

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

1. Dezember 2026

Primärer Abschluss (Geschätzt)

1. Januar 2029

Studienabschluss (Geschätzt)

1. Januar 2029

Studienanmeldedaten

Zuerst eingereicht

9. November 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

9. November 2026

Zuerst gepostet (Tatsächlich)

13. November 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

13. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

9. November 2026

Zuletzt verifiziert

1. Oktober 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

JA

Beschreibung des IPD-Plans

All participant data will be shared via peer-reviewed publication as a combined summary. Any individual outcomes published per subject will be deidentified utilizing the subject ID (eg. Dose level, demographics, adverse events etc.)

IPD-Sharing-Zeitrahmen

Data included in the peer reviewed publication will be publicly available. No raw data will be shared.

IPD-Sharing-Zugriffskriterien

A peer-reviewed publication will be made available according to the publishing journal's specifications. CCF personnel will not share study data apart from that which has been published publicly

Art der unterstützenden IPD-Freigabeinformationen

  • STUDIENPROTOKOLL
  • SAFT
  • ICF

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Ja

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Produkt, das in den USA hergestellt und aus den USA exportiert wird

Ja

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren